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Metastatic switchThe formation of melanoma metastases from primary tumor cells is a complex phenomenon that involves the
regulation of multiple genes. We have previously shown that the receptor for advanced glycation end products
(RAGE) was up-regulated in late metastatic stages of melanoma patient samples and we hypothesized that up-
regulation of RAGE in cells forming a primary melanoma tumor could contribute to the metastatic switch of
these cells. To test our hypothesis, we overexpressed RAGE in the WM115 human melanoma cell line that was
established from a primary melanoma tumor of a patient. We show here that overexpression of RAGE in these
cells is associated with mesenchymal-like morphologies of the cells. These cells demonstrate higher migration
abilities and reduced proliferation properties, suggesting that the cells have switched to a metastatic phenotype.
At the molecular level, we show that RAGE overexpression is associated with the up-regulation of the RAGE li-
gand S100B and the down-regulation of p53, ERK1/2, cyclin E and NF-kB. Our study supports a role of RAGE in
the metastatic switch of melanoma cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The receptor for advanced glycation end products (RAGE) is
expressed during early development, but repressed in most adult
tissues, except in the lungs, and is found up-regulated in a large number
of pathologies such as diabetes, Alzheimer's disease and in many
cancers [1,2]. RAGE is activated by structurally unrelated ligands such
as the advanced glycation end products (AGEs), HMGB1, or members
of the S100 protein family, that are associated with tissue damage and
pathological conditions [3–10]. Due to the diversity of its ligands,
RAGE is classiﬁed as a pattern recognition receptor. RAGE signaling is
complex and depends on ligands and cell types [11]. For instance, in
colon, gastric, breast, pancreatic and liver cancer tissues RAGE is found
up-regulated and suppression of RAGE expression or RAGE signaling re-
duces cellular proliferation and/or migration [12–17]. However, in lung
carcinomas and rhabdomyosarcoma, it is the down-regulation of RAGE
that results in increased cellular proliferation and/or migration [18,19],
suggesting that the role of RAGE is cancer speciﬁc and depends of the
tissue and tumor environment [20–22].
The goal of this studywas to elucidate the role of RAGE upregulation
in melanoma. In melanoma, RAGE has been detected at high levels in aend products; AGEs, advanced
1 protein; EMT, epithelial mes-
sity, Dept. 2665, PO BOX 6050,
1 231 8333.subset of metastatic tumor samples, both at the transcription and protein
levels [12,23], suggesting that RAGE might contribute to tumor develop-
ment only in certain melanoma tumors [23]. It was also shown that the
metastatic humanmelanoma cells G361 showed higher levels of cellular
proliferation and migration in the presence of RAGE activating AGE
ligands [24] and that cellular proliferation could be blocked by anti-
RAGE antibodies [24]. Similarly, anti-RAGE antibodies have been shown
to reduce the growth of melanoma tumor xenografts in mice implanted
with G361 melanoma cells [24]. In a different study, RAGE was shown
to promote the formation of B16F10 melanoma metastases in mice [25].
Based on these data, we hypothesized that RAGE may contribute
signiﬁcantly to melanoma tumor cell proliferation and/or metastases
formation in the population of melanoma tumors where RAGE is up-
regulated. To test our hypothesis, we overexpressed RAGE in a melano-
ma cell line (WM115) that originates from a primary melanoma tumor
and compared the cellular proliferation and migration of populations of
WM115 cells that differed only by their level of RAGE.We observed that
the cells expressing high levels of RAGE presented an altered morphol-
ogy with an elongated mesenchymal-like shape that is a typical feature
of metastatic cells. Interestingly, we observed that the RAGE overex-
pressing cells migrated at higher levels and showed reduced cellular
proliferation compared to control cells suggesting that RAGE up-
regulation led to a metastatic switch [26]. At the molecular level, we
showed that the RAGE overexpressing cells produced higher levels of
S100B, which is used as a prognostic marker in melanoma patients
[27–29]. In addition, we found lower levels of the tumor suppressor
p53 protein, cyclin E as well as of ERK1/2 in the cells overexpressing
RAGE, which supports the reduced cellular proliferation observed.
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2.1. Cell lines and transfection
The human melanoma cell lines WM115 and WM266 were pur-
chased from ATCC and grown in Opti-MEM (Invitrogen, Carlsbad, CA)
supplemented with 4% FBS (Invitrogen) in the presence of penicillin
and streptomycin (JR Scientiﬁc, Woodland, CA), 5% CO2 and at 37 °C.
The cells were stably transfected with pcDNA3 expressing full-length
RAGE (a gift from Prof. C.W. Heizmann, Children's Hospital, Zürich,
Switzerland) using the SatisFection (Stratagene, Santa Clara, CA)
or the X-tremeGENE 9 (Roche Applied Science, Indianapolis, IN)
transfection reagents according to the manufacturer's protocols. Cells
transfected with the empty pcDNA3 vector were used as negative con-
trol cells (WM115-MOCK andWM266-MOCK). Prior to transfection, all
plasmids were linearized with MfeI. The transfected cells were selected
by limited dilution in the presence of 1 mg/ml G418 (WM-115-RAGE
and WM115-I) or 0.5 mg/ml G418 (WM115-MOCK).
Transfection ofWM115-RAGE andWM115-MOCKwith RAGE siRNA
(sc-37007) or S100B siRNA (sc-43356) (Santa Cruz Biotechnology,
Dallas, TX) was performed according to procedures recommended by
the manufacturer. Brieﬂy, cells were seeded and grown to 60%–80%
conﬂuence, in 6 well plates in Opti-MEM (Invitrogen) and 4% FBS. The
transfection was performed in the absence of serum. The cells were col-
lected after 48 h and cell lysates were prepared for RT-PCR analysis
(Section 2.2) or ELISA (Section 2.5).
2.2. Real-time PCR (RT-PCR)
RNAs were extracted using a commercial kit (Ambion, Invitrogen)
according to the manufacturer's instructions. The quality of the RNA
was assessed by absorbance spectroscopy and by agarose gel electro-
phoresis. The RNAwas reverse transcribed into cDNA using the Reverse
Transcription System from Promega (Madison, WI).
The real time PCR (RT-PCR) was run with 20 ng cDNA per well on a
Stratagene Mx3000p thermocycler using the Brilliant II SYBER Green
QPCR Master mix (Stratagene). The genes of β-actin and glyceraldyde-
3-phosphate dehydrogenase (GAPDH) were used as housekeeping
genes. The primers used to detect the transcripts of RAGE, S100B,
S100A2, S100A6, S100A10 and β-actin are listed in a previous publica-
tion [23]. The other primers were as follows: GAPDH_Forward: GAAG
GTGAAGGTCGGAGTC; GAPDH_Reverse: GAAGATGGTGATGGGATTTC;
p53_Forward: CCAGGGCAGCTACGGTTTC; and p53_Reverse: CTCCGTCA
TGTGCTGTGACTG. The following RT-PCR program was used: 10 min at
95 °C followed by 40 cycles of 30 s at 95 °C, 30 s at 58 °C, and 30 s at
72 °C. A melting curve was recorded at the end of the cycles to evaluate
the quality of the ampliﬁed products.
The Ct values for each gene were calculated and normalized to
β-actin and GAPDH (ΔCt = Ctgene− Ctactin or GAPDH). Since similar ΔCt
values were obtained with the housekeeping genes β-actin and
GAPDH, only the delta Ct normalized with β-actin are shown. The ΔCt
obtained from RAGE transfected cells were then compared to
MOCK transfected cells (Δ(ΔCt) = ΔCtRAGE − ΔCtMOCK). For each
gene, the fold of change (Fgene) of gene expression was calculated
using F = 2Δ(ΔCt). The experiments were run in triplicate using cDNAs
obtained from three independent RNA preparations. The standard devi-
ations were calculated from the folds of changes in gene expression.
2.3. Immunoﬂuorescence
For staining the actin ﬁlaments, cells were seeded on microscope
chamber slides (BD Biosciences, San Jose, CA) overnight, ﬁxed with
3.7% paraformaldehyde followed by permeabilization with 0.1% Triton
X-100. The cells were then blocked with 3% BSA in PBS prior to incuba-
tion with sulforhodamine 101 conjugated phalloidin (1/40 dilution)
(Biotium, Hayward, CA). Nuclear staining was performed by addingHoechst 33342 (Invitrogen) in PBS. The microscope slides were exam-
ined using a Zeiss AxioObserver Z1 inverted microscope with a 40×
magniﬁcation.
The ellipticity of the cells and nuclei of the WM115-MOCK and
WM115-RAGE cells was assessed by calculating the ratio of the length
over the width of at least 30 cells and their corresponding nuclei.
2.4. Flow cytometry
Flow cytometric measurements were performed on a C6 Accuri ﬂow
cytometer (Accuri, Ann Arbor, MI). The cells were gently detached with
a cell scrapper and incubated on ice with a serial dilution of a mouse
anti-RAGE antibody (Mab 1145, R&D Systems, Minneapolis, MN). After
PBS washes, the cells were further incubated with a FITC-conjugated sec-
ondary anti-mouse antibody (10 μg/ml, Jackson ImmunoResearch, West
Grove, PA). Themeanﬂuorescence of 5000 events per samplewas plotted
as a function of the antibody concentration. The data were ﬁtted with
a 1:1 binding model using the KaleidaGraph software (Synergy). The ex-
periments were performed in triplicate.
Cell cycle analysis was performed on the same instrument using
propidium iodide (PI) (Calbiochem) and an antibody against cyclin E
(H12, Santa Cruz). Brieﬂy, 60–80% conﬂuent WM115-MOCK and
WM115-RAGE cells were ﬁxed with 70% alcohol, and permeabilized
with Triton X-100 prior to incubation with cyclin E antibody and PI, ac-
cording to the published procedures [30]. A FITC-conjugated secondary
antibody (Jackson ImmunoResearch) was used to detect the bound pri-
mary anti-cyclin E antibody. The ﬂuorescence of PI was used to identify
the G1, S and G2/M phases of the cell cycle and to gate the cells. To com-
pare the level of cyclin E in the different phases of the cell cycle, the
mean ﬂuorescence of FITC was reported for each population of gated
cells. The experiment was performed independently twice using tripli-
cate samples in each experiment.
2.5. ELISA
Cell extracts were prepared using a commercial kit (Paris, Invitrogen)
and the protein content was determined with the Pierce BCA protein
assay kit (Pierce/Thermo Scientiﬁc, Rockford, IL). RAGE protein levels in
the cell extracts were determined using the Quantikine human RAGE
Immunoassay kit (R&D Systems) according to the manufacturer's proce-
dure, and expressed in picogram of RAGE per mg of total protein.
S100B levels in the cell extracts and the conditionedmedia were de-
terminedwith the help of a calibration curve obtained from a sandwich
ELISA. For the sandwich ELISA, we used a polyclonal anti-S100B anti-
body (DakoCytomation, Denmark) to capture S100B. A calibration
curve was performed using recombinant human S100B (0.01 nM to
150 nM), whichwas puriﬁed according to the standard procedures [31].
To detect bound S100B, we used a second anti-S100B antibody
(MAB1820, R&DSystems). The detectionwas performedusing an alkaline
phosphatase-conjugated (AP) secondary antibody and para-nitrophenyl
phosphate as substrate. The cell lysate and conditioned media samples
from two independent experiments were run in duplicate.
2.6. Western blots
Cell extracts were prepared using a commercial kit (Paris, Invitrogen)
and the protein concentration in the cell extracts was determined as de-
scribed above. The proteins (20–100 μg) were resolved on 10 or 15% SDS
PAGE and blotted against nitro-cellulose membranes. The blots were
blockedwith 3% BSA in TBS (50mMTris pH 7.4, 150mMNaCl) and incu-
bated with the primary antibody diluted in 1% BSA in TBS. HRP conjugat-
ed secondary antibodies (donkey anti-rabbit, goat anti-mouse and rabbit
anti-goat) were all from Jackson ImmunoResearch and used at dilutions
recommended by the manufacturer. The primary antibodies against
β-actin (#4970), Akt (#4691), phospho-Akt (Ser473, #4060S), SAPK/JNK
(#9258), phospho-SAPK/JNK (#4668, Thr183/Tyr185), p44/42 (#4695)
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naling (Danvers, MA). Antibodies against p53 (sc-47698) and Dia-1
(sc-373807) were from Santa-Cruz Biotechnology (Dallas, TX). Anti-
S100B (#Z0311) was from DakoCytomation (Denmark) and anti-
S100A10 (#ab52272) was from Abcam (Cambridge, MA). The cyclin E
antibody (#630701) was from BioLegend (San Diego, CA). Rabbit sera
directed against S100A2, A6 and A4 were generous gifts from Prof.
Heizmann (Children's Hospital, Zurich, Switzerland). The blots were
developed using a chemoluminescent substrate (Pierce ECL Western
Blotting Substrate, Thermo Scientiﬁc). The blots were scanned and the
intensities of the scanned bandswere determined using the ImageJ soft-
ware [32]. Following the staining for S100 proteins, p53 and cyclin E, the
blots were stripped using standard conditions, which consisted of 45
min incubation at 50 °C in the presence of 200 mM glycine buffer at
pH 2.2, and re-stained for actin. For the staining of AKT/P-AKT, JNK, p-
JNK, and ERK/p-ERK, the blots were ﬁrst stained with the antibodies
recognizing the phosphorylated form of the proteins and, when indi-
cated in the ﬁgure legend, the blot was stripped and re-stained with
the antibody recognizing the total forms (phosphorylated and non-
phosphorylated) of the protein. Alternatively, samples from the same
cellular extracts were loaded onto different wells of SDS-PAGE gels.
After electroblotting, the blot was cut into parts that were used for
separate Western blot analysis.
2.7. Cell assays
2.7.1. Alamar Blue assay
The cells were seeded (4 × 104 cells/well) in 24 well plates and
incubated in Opti-MEM as described above. When the cells reached
70–80% conﬂuency, Alamar Blue (1/10 dilution, Nalgene) was added
to the wells and the plate was further incubated for 3 h or 4 h at
37 °C. The reduced form of Alamar Blue was detected by ﬂuorescence
spectroscopy (Ex: 540 nm; Em: 590 nm) [33] and corrected for the
ﬂuorescence emission of AB in the cell culture medium only. The exper-
iments were performed in triplicate.
2.7.2. Migration assay
The cells were added (104 cells/well) to the top of 8 μm ﬁlter inserts
(24 well plate, Greiner Bio-One). The inserts were then added into the
wells of a 24 well plate containing Opti-MEM and 4% FBS. After 24 h in-
cubation at 37 °C, the cells on top of the ﬁlter were gently removed
using cotton swabs. Alamar Blue (1/10 dilution, Nalgene) was added
to the wells and its ﬂuorescence emission (Ex: 540 nm; Em: 590 nm)
wasmeasured after 9 h or 10 h further incubation. The wells containing
either the cell culture media alone or the seeded cells without insert
were used as negative and positive controls, respectively.When indicat-
ed, a polyclonal anti-S100B antibody (DakoCytomation) or polyclonal
anti-RAGE antibody (100 nM) was added to the cells at the time point
of seeding into wells. The polyclonal anti-RAGE antibody consisted
of an equimolar mixture of anti-V, anti-C1 and anti-C2 antibodies as
described in our previous publications [34,35].
2.7.3. Invasion assay
The assay was performed similarly to the migration assay with the
exception that the insert ﬁlters were coated with a solution of bovine
collagen I (Santa Cruz Biotechnology, Santa Cruz, CA) prior to the
addition of the cells. Themigration and invasion experiments were per-
formed in triplicate.
2.7.4. Soft agar colony formation assay
Cell suspensions (1 × 104 cells/well) were mixed (1:1) with 1.4%
agarose in Opti-MEM containing 8% FBS and added on top of the wells
containing solidiﬁed 1% agarose. After solidiﬁcation of the soft agarose,
the cell culture medium (Opti-MEM containing 4% FBS) was added to
the wells. The plate was then incubated for 4 to 5 weeks at 37 °C and
fresh medium was added to the plate every 3 to 4 days. The coloniesformed were visualized by staining with crystal violet. The colonies in
ten different ﬁelds were counted.
2.7.5. Wound healing assay
The cells were seeded in 96well plates and incubated until reaching
90% to 100% conﬂuence. Awoundwas performed using the tip of sterile
P10pipet tip. Thewellswere imaged at the indicated timepoints using a
CCD camera attached to an Olympus Fluoview microscope.
2.8. NF-κB assay
The cells were seeded (104 cells/well) in 24 well plates and incubat-
ed until they reached 60–70% conﬂuence. The cells were then co-
transfected with the NF-κB cis-Reporting System (# 219077; Strata-
gene) containing a luciferase encoding gene and the monster GFP
plasmid (SABiosciences) that was used to estimate the transfection efﬁ-
ciency. The transfectionwas performed using the X-tremeGENE 9 trans-
fection reagent (Roche Applied Science, Indianapolis, IN) according to
the manufacturer's protocols. The pFC-MEKK plasmid was used in co-
transfection experimentswith theNF-κB plasmid and served as positive
control.
Following transfection (24 h–48 h), the cells were lysed using the
Reporter lysis buffer (Promega,Madison,WI). The activity of the lucifer-
ase was determined using a commercial luciferase detection system
(# E1500; Promega) on a Quick-Pak Quantiﬁer luminometer.
2.9. Statistical analysis
The migration and invasion assays were replicated at least three
times using 6 wells for each condition. All other experiments were
also performed in duplicate or triplicate, as indicated. Themean± stan-
dard deviation is reported. Statistical signiﬁcances between groups
were determined using the Student's t-test or one-way ANOVA using
Bonferroni Post-Hoc test.
3. Results
3.1. Overexpression of RAGE in WM115 cells and characterization of the
transfected cell lines
To determine the effect of RAGE up-regulation in melanoma cells,
we stably transfected theWM115melanoma cell linewith a vector cod-
ing for full-lengthRAGE.WM115 cells stably transfectedwith the empty
vector (WM115-MOCK) were used as negative control. To characterize
the transfected cells, we determined the levels of RAGE mRNA and pro-
tein by RT-PCR and ELISA, respectively. From two independent transfec-
tion procedures, we selected two clones WM115-RAGE and WM115-
RAGE-I, which overexpressed RAGE, at the protein levels, 94-fold and
7-fold, respectively, when compared to the WM115-MOCK controls.
WM115-MOCK cells expressed 11.5 ± 0.1 pg RAGE per mg of total pro-
tein and WM115-RAGE cells expressed 1081.3 ± 53.0 pg RAGE per mg
total protein (Fig. 1A). The second transfected cell line WM115-RAGE-I
expressed 81.0 ± 2.0 pg RAGE per mg total protein. The expression of
RAGE at the protein level reﬂected the levels of transcripts thatwere de-
termined by RT-PCR. We also measured the level of RAGE in WM-266
cells. This cell-line (WM266) originates from the same patient as the
WM115, but was established from a metastatic tumor [36]. RAGE pro-
tein levels in WM266-MOCK were 2.4 higher than in WM115-MOCK
cells and were equal to 24.4 ± 5.4 pg per mg of protein.
To ensure that in the transfected cells RAGE was properly processed
and exported to the cell surface, wemeasured the binding of anti-RAGE
antibodies to cell surface RAGE by ﬂow cytometry (Fig. 1B). We found
that the antibodies bound to larger numbers of RAGE receptors in
RAGE overexpressing cells than in control cells.
Fig. 1. A: Levels of RAGE in RAGE transfectedWM115 cells as determined by ELISA. Levels are expressed in pg RAGE protein per mg of total protein. WM115-RAGE andWM115-RAGE-I
expressed 94 fold and 7 fold higher RAGE protein than theMOCK control cells, respectively. B: Binding of the anti-RAGE antibodyMAB1145 toWM115-RAGE (ﬁlled circles) andWM115-
MOCK (ﬁlled squares)measured by ﬂow cytometry. The binding curve ofMAB1145 toWM115-RAGEwasﬁtted using a 1:1 bindingmodel and showed an afﬁnity of 1.5 (±0.3) nM. RAGE
overexpressed in themelanoma cells is properly processed and translocated to the cell-surface, as demonstrated by their recognition by speciﬁc antibodies. The experimentwasperformed
in triplicate and the standard deviation is indicated. C–F: Morphology of WM115-MOCK (C), WM115-RAGE-I (D), WM115-RAGE (E) and WM266-MOCK (F) by bright ﬁeld microscopy.
G–H:Differences inmorphology betweenWM115-MOCK (G) andWM115-RAGE (H) transfected cells, as shown by actin staining. Actinwas stainedwith PE conjugated phalloidin and the
nuclei were stained with Hoechst 33342. (20× magniﬁcation).
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and actin remodeling
We observed large differences in morphologies between the
WM115-MOCK,WM115-RAGE-I andWM115-RAGE cell lines. Whereas
the WM115-MOCK cells presented the classical epithelial morphology
as previously described for this cell line (Fig. 1C) [37,38], the RAGE
transfected cells showed a more elongated morphology resembling
that of ﬁbroblasts (Fig. 1E). We also measured the length and width of
the cells and found that the ratio (R) of the length over the width was
signiﬁcantly larger (p b 0.001) in RAGE transfected cells than in MOCK
control cells (RMOCK=1.77±0.68 versus RRAGE=9.85± 3.8). Interest-
ingly, theWM115-RAGE-I cells that expressed RAGE at an intermediate
level also showed an “intermediate” morphology between those of
WM115-MOCK and WM115-RAGE (Fig. 1D). We also compared the
morphologies of WM115-RAGE and WM266-MOCK, the “sister” cell
line of WM115 [36]. We observed that WM266-MOCK presented simi-
lar elongated shape thanWM115-RAGE (Fig. 1F). Since the architecture
of cells is under the control of actin ﬁlaments, we also investigated the
distribution of F-actin ﬁlaments in the transfected cells by ﬂuorescence
microscopy, using sulforhodamine conjugated phalloidin. We observed
differences in organization of the actin ﬁlaments between the two cell
lines. In the WM115-MOCK cells, many structures resembled short
cortical bundles (Fig. 1G), these structures appeared to be absent in
the WM115-RAGE cells (Fig. 1H). Instead in the RAGE-overexpressing
cells, longer parallel ﬁbers were observed as well as structures that re-
semble collapsed F-actin (Fig. 1H). These changes in actin organization
resemble the changes occurring during the epithelial mesenchymal
transition (EMT) of cancer cells [39,40].Fig. 2. Comparison of the cellular proliferation of WM115-MOCK andWM115-RAGE cells
using Alamar Blue. Excitation was performed at 540 nm and the ﬂuorescence emission
was recorded at 590 nm. The experiment was performed at least three times with 4–6
replicates each time.3.3. RAGE overexpression causes changes in cell proliferation andmigration
In order to determine the effect of RAGE overexpression on the
cellular behavior of theWM115melanoma cells, we compared the pro-
liferation and migration properties of these cells compared to MOCKcontrols. To our surprise, we did not observe an increase but rather a
signiﬁcant 30% decrease in cellular proliferation in the WM115-RAGE
cells compared to the MOCK cells (Fig. 2).
We tested several metastatic properties of the transfected cells and
as a ﬁrst step, we studied the growth of the cells in the absence of sup-
port or anchor, a phenomenonwhich is also referred as anoikis [41–44].
In these conditions, we observed that the WM115-RAGE cells formed a
signiﬁcantly larger number of colonies (19 ± 5 colonies; p b 0.01) than
the WM115-MOCK cells (7 ± 3 colonies) (Fig. 3A, B).
We next compared the migration properties of the melanoma cells
using standard Boyden chamber assays. We found that after 24 h, a sig-
niﬁcantly larger number of WM115-RAGE cells had migrated through
the ﬁlter (33 ± 4.5%; p b 0.01) compared to the WM115-MOCK cells
(14± 1.9%) (Fig. 4A).We also observed that the percentage ofmigrated
WM115-RAGE cells was not signiﬁcantly different from the percentage
of migrated WM266-MOCK cells (27.9 ± 4.2%).
Fig. 3.A: Soft agar assaywithWM115-MOCK (a–c) andWM115-RAGE cells (d–f). Three representativeﬁelds are shown for each type of cells. The colonieswere stainedwith crystal violet.
B: Averaged number of colonies per ﬁeld. Three independent experiments were performed, **p b 0.01.
Fig. 4. A–B: Migration and invasion assays. A: Percentage of migrated cells (WM115-MOCK,
WM115-RAGE, WM115-RAGE-I andWM266-MOCK). B: Percentage of invaded cells (WM115-
MOCK,WM115-RAGE-I andWM115-RAGE).Alamarbluewasused todetermine thepercentage
ofmigrated and invaded cells. Themean values of three independent experiments performed in
triplicates are indicated with their standard deviations (*p b 0.05; **p b 0.01).
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cells correlated with the level of RAGE in these cells. We indeed ob-
served that the WM115-RAGE-I cells migrated to a level (19 ± 3.2%)
that was intermediate between that of the WM115-MOCK cells
(14 ± 1.9%) and that of theWM115-RAGE cells (33± 4.5%), the differ-
ence of percentage of migrated cells being statistically signiﬁcant
between the three groups (p b 0.05) (Fig. 4A).
In addition, we investigated the invasion properties of these cells
and observed that a signiﬁcantly larger number of WM115-RAGE cells
had invaded collagen-coated ﬁlters (18.5% ± 1%, p b 0.05) than the
WM115-MOCK cells (8% ± 4.5%) (Fig. 4B).
To complement our ﬁndings, we compared the migration abilities
of the melanoma cells after the formation of a wound on a layer of
conﬂuent cells (Fig. 5). In agreement with the Boyden chamber assay
results, we observed that theWM115-RAGE cells (Fig. 5, lower row) re-
covered the wounded area signiﬁcantly faster than the MOCK control
cells (Fig. 5, upper row).
To further support our hypothesis that RAGE overexpression in the
WM115 cell line was responsible for the observed changes in cellular
migration, we tested whether RAGE suppression by siRNA in the
WM115-RAGE cells could revert the increased migration. We observed
that suppression of RAGE by speciﬁc siRNA signiﬁcantly reduced
(p b 0.05) the percentage of migrated cells from 49% ± 1% (control
siRNA) to 39% ± 5% (RAGE siRNA) (Fig. 6A). The level of suppression
at the protein levelwasmeasured by ELISA and showed a 3.2 fold reduc-
tion (±1.5) after transfection with siRNA (Fig. 6B). In addition, we
observed that RAGE suppression resulted in a signiﬁcant (p b 0.01)
increase in cellular proliferation (Fig. 6C).
3.4. RAGE overexpression is accompanied with the up-regulation of S100B
Sincewe showed that the RAGE overexpressing cells acquired sever-
al metastatic properties, our next goal was to interrogate the levels of
RAGE ligands in the transfected cells. We chose to compare the levels
of several S100 proteins that are relevant to melanoma and therefore
measured the levels of S100A2, S100A4, S100A6, S100A10 and S100B
in cell extracts of the different cell-lines. Among those S100 proteins,
Fig. 5.Wound healing assay. Top row: Assay with WM115-MOCK cells. Bottom row: Assay with WM115-RAGE cells. After wounding the conﬂuent cells with a pipet tip, the RAGE
transfected cells (bottom row) recovered the wounded area faster than theMOCK transfected cells (top row). Three independent experiments were performed and show similar results.
The ﬁgure shows a representative experiment. The pictures of the wounded area were taken at t = 0 h; t = 14 h and t = 24 h.
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levels inWM115-RAGE cells were (4.6± 0.7) higher than in the control
WM115-MOCK cells. At the protein level, S100B levels were also signif-
icantly higher in WM115-RAGE cells than in WM115-MOCK cells as
determined by Western blot (2.5 ± 0.7) and ELISA (2.7 ± 1.4) (Fig. 7).
In addition, we found that WM115-RAGE cells secreted higher levels
of S100B in the media (8.2 ± 1.5 fold) than the WM115-MOCK cells
(Fig. 7B).
Interestingly, suppression of RAGE by siRNA in the WM115-RAGE
cells did not result in a signiﬁcant reduction in the levels of intracellular
S100B protein (data not shown). To test the hypothesis that S100B par-
ticipates in the increased migration of WM115-RAGE cells, we com-
pared the migration of these cells after suppressing extracellular
RAGE/S100B interaction with anti-S100B antibodies (DakoCytomation)
or suppressing intracellular S100B using siRNA (Fig. 8). S100B suppres-
sion by siRNA resulted in a 8.5 (±3.3) fold decrease in S100B transcript
levels. We observed no changes in migration in theWM115-RAGE cells
after treatment with either S100B antibodies or S100B speciﬁc siRNA
suggesting that the changes in migration in theWM115-RAGE cells oc-
curred in a S100B independent manner (Fig. 8). To test the hypothesis
that other RAGE ligands might stimulate the migration of the WM115-
RAGE cells, we compared the migration of these cells after treatment
with anti-RAGE antibodies. We could not detect changes in migrationFig. 6. Effect of RAGE blockage by siRNA on cellularmigration and proliferation ofWM115-RAGE
siRNA. B: Protein RAGE levels following suppression with RAGE siRNA. C: Changes in cellular pof either WM115-MOCK or WM115-RAGE cells after treatment with
polyclonal anti-RAGE antibodies (data not shown), suggesting that the
increase in migration of the WM115-RAGE cells occurred in a RAGE-
ligand independent manner.
3.5. Overexpression of RAGE results in decreased levels of the tumor
suppressor p53 and cyclin E
Following the observation that S100B levels were up-regulated in the
WM115-RAGE cells, we next investigated the levels of possible intracellu-
lar targets of S100B relevant in cancer and melanoma. One of these
targets is the tumor suppressor protein p53 and the mechanism of inter-
action of S100B with p53 has been well documented [28,45,46]. We
observed that the level of p53 was signiﬁcantly lower in the WM115-
RAGE cells than in the MOCK control cells, both at the transcription
(2.6 ±0.3 fold) andprotein levels (1.9±0.4 fold) (Fig. 9A).We alsomea-
sured the levels of the cell cycle regulator cyclin E, and found signiﬁcantly
lower protein levels of cyclin E (4.0 ± 1.2 fold) in RAGE overexpressing
cells than in MOCK controls (Fig. 9B). To further support our ﬁndings,
we analyzed the level of cyclin E during the different phases of the
cell cycle (G1, S andG2/M) by ﬂow cytometry. Our data shows that cyclin
E was signiﬁcantly reduced (p b 0.01) in all phases of the cell cycle
(Fig. 9C).cells. A:Migration ofWM115-RAGE following transfectionwith control and RAGE speciﬁc
roliferation of WM115-RAGE following transfection with control and RAGE speciﬁc siRNA.
Fig. 7. A: Detection of S100B, S100A6 and S100A10 in cell lysates by Western blot. Three
independent cell lysateswere prepared and analyzed. Theﬁgure shows the representative
blot of one cell lysate. Thedetection of actinwasperformedusing the same lanes thatwere
used for the detection of S100 proteins. B: Detection of S100B in cell lysates and superna-
tant as determined by ELISA.
Fig. 9. A: Levels of p53 protein in WM115-MOCK and WM115-RAGE as determined by
Western blot. Antibodies against β-actin were used as loading control, in the same lanes
that were used for p53 staining. B: Levels of cyclin E in cell lysates of WM115-MOCK
and WM115-RAGE as determined by Western blot. Antibodies against β-actin were
used for the loading control and the actin staining was performed on the same lanes
that were used for the cyclin E staining. C: Level of cyclin E in the different phases G1, S
and G2/M of the cell cycle. PI was used to gate the cells according to cell cycle phases. A
FITC-labeled secondary antibody was used to detect bound anti-cyclin E.
Fig. 8. Effect of S100B blockage by siRNA and RAGE/S100B interaction by anti-RAGE anti-
bodies on the migration of WM115-RAGE cells. Following transfection with S100B siRNA,
RAGE levels were decreased by 8.5 fold (±3.3) as determined by RT-PCR. Ctrl (siRNA)
indicates that the cells were transfected with a negative control siRNA.
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The transcription factor NF-κB has been shown to promote mul-
tiple processes in cancer such as proliferation, invasion, metastasis,
angiogenesis, and chemo- and radioresistance [47–49]. We hence
determined whether RAGE overexpression inﬂuenced the activity of
NF-κB. For this purpose, we transfected both WM115-MOCK and
WM115-RAGE with a luciferase/NF-κB reporter system and observed
that the basal activity of NF-κB was signiﬁcantly reduced in the RAGE-
transfected cells and was only 37% of the level in the control cells
(Fig. 10A).Fig. 10.A: Activity of NF-kB inWM115-MOCK andWM115-RAGE cells. The activity of NF-kB
was determined using a luciferase/NF-kB reporter system. B: Detection of AKT, ERK1/2 and
SAPK/JNK in cell lysates by Western blot. Three independent cell lysates were prepared
and analyzed. The intensities of the bands corresponding to the non-phosphorylated and
phosphorylated forms of each kinase (AKT, p-AKT; SAPK/JNK, p-SAPK/JNK and ERK1/2,
p-ERK1/2) were compared by densitometric analysis. The ﬁgure shows a representative
blot of cell lysates. The same cellular extract was loaded onto different wells of the gel and
blotted. After electroblotting, the blotwas cut into twoparts and eachpartwas stained either
for the total forms of AKT, JNK and ERK1/2 or for the phosphorylated forms of the proteins.
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phosphorylation
We next analyzed the activity of several signaling kinases that are
relevant in cancer and melanoma and we investigated the levels of
ERK1/2, AKT and JNK/SAPK in cell extracts. We observed a 1.8 (±0.5)
fold reduction of the levels of phosphorylated ERK1/2 in WM115-
RAGE cells compared to the control cells (Fig. 10B). However, we did
not observe differences in phosphorylated Akt or JNK between the
two cell lines (Fig. 10B).
4. Discussion
The mechanisms by which RAGE contributes to cancer are not clear
and may differ between cancer types [20–22]. Indeed, although RAGE
up-regulation correlates with increased cellular proliferation and
migration in many cancers (colon, gastric, breast, pancreatic and liver
cancer) [12–17], it is the down-regulation of RAGE that correlates
with increased proliferation and migration in lung carcinomas and
rhabdomyosarcoma [18,19].
We previously showed that RAGE transcript levels varied greatly
among stage III and IV melanoma tumor samples, suggesting that the
role of RAGE in melanomamay be tumor speciﬁc [23]. To better under-
stand the function of RAGE inmelanoma progression, we chose to com-
pare the proliferation and migration properties of the WM115 primary
melanoma cell line following overexpression of RAGE. We chose the
WM115 cell line because i) it was established from a primary tumor
of a melanoma patient, ii) it has low basal levels of RAGE expression
and iii) the metastatic cell line WM266, which was established from
the same patient, was also available. Therefore, we were able to
compare the metastatic properties of the WM115 cell line, after RAGE
overexpression, to those of the sister metastatic cell line WM266.
We ﬁrst observed that RAGE overexpression in WM115 cells result-
ed in changes in both cellmorphology and actin remodeling, resembling
the epithelial mesenchymal transition (EMT) characteristic of metasta-
tic cells [39]. In addition to the change in cell morphology and the
increase in cell ellipticity (Fig. 1), we noticed that the nuclei of the
RAGE overexpressing cells were also notably more elongated than
those of the control MOCK cells. As observed with the cells, comparison
of the ratio (R) of the length over width of the nuclei showed a signiﬁ-
cant (p b 0.001) difference in ellipticity between the two cell lines.
(RNuclei-MOCK = 1.4 ± 0.3 versus RNuclei-RAGE = 1.8 ± 0.5). Studies
have shown that the nuclear shape is tightly regulated by the cell mor-
phology and that the nuclear morphology could reﬂect changes in cell
health [50,51]. In addition, defects in nuclear shape are also used in clin-
ical settings as markers of disease [51]. The changes in nuclear shape
that we observed following RAGE overexpression are thus consistent
with the observed changes in cell morphology and the accompanied
changes in cellular proliferation and migration properties. We also ob-
served that RAGE overexpression increased signiﬁcantly the mobility
of the melanoma cells in all assays used by us, i.e. migration, invasion,
anchorage independent colony formation and wound healing assays
(Figs. 3 and 5). It thus appears that high levels of RAGE confer
the WM115 cells a metastatic phenotype by inducing an epithelial–
mesenchymal like transition. Our results are in agreement with earlier
studies by Huttunen et al. who showed that B16 mouse melanoma
cells overexpressing full-length RAGE produced a larger number of me-
tastases than the B16 cells overexpressing a signaling incompetent form
of RAGE that lacked the intracellular signaling domain [52]. Although
RAGE overexpression in WM115 cells correlated with increased migra-
tion properties, other genes and proteins are involved in this complex
process as demonstrated by many studies aiming at identifying meta-
static melanoma gene expression signatures [53–56]. Indeed, we ob-
served that in our experimental conditions, the WM266-MOCK cells
had similar migration properties to the WM115-RAGE cells. However,
in the WM266-MOCK cells, the level of RAGE is only 2.4 fold higherthan in WM115-MOCK cells (24.4 ± 5.4 pg RAGE per mg of protein
versus 11.5+ 0.1 pg RAGE permg of total protein, respectively). Our re-
sults demonstrate that overexpression of RAGE was sufﬁcient to induce
metastatic properties in theWM115 cell line, however, theWM266 cell
line displays a metastatic phenotype despite only minimal increase in
RAGE expression, suggesting that other genes are also involved in this
process.
RAGE overexpression also resulted in decreased proliferation
abilities of the cells, suggesting that RAGE triggered a phenomenon
described as the metastatic switch, where the migration properties of
cells are increased at the expenses of the proliferative capabilities of
the cells [26]. The observed reduction in cell proliferation in RAGE over-
expressing cells correlated with a decrease in levels of cyclin E in all cell
cycle phases (Fig. 9C). Cyclin E can regulate cell proliferation by cyclin
dependent kinase 2 (cdk2) dependent and independent processes
resulting in cell cycle progression [57]. Overexpression of cyclin E
has been previously observed in WM115 melanoma cells and was
associated with the hyper-proliferative nature of this cell line [58]. To
demonstrate that RAGE overexpression correlated to reduced cellular
proliferation of the WM115 cells, we investigated if these effects were
reversible, using speciﬁc RAGE siRNA. We observed that suppression
of RAGE resulted in a signiﬁcant (p b 0.01) increase in cellular prolifer-
ation (Fig. 6C), supporting our hypothesis that in melanoma cells, RAGE
overexpression can control the metastatic switch.
One of the current prognostic markers for metastatic melanoma pa-
tients is S100B [27–29]. We show here that theWM115-RAGE cells ex-
press and release signiﬁcantly larger amounts of S100B than the control
cells. Thisﬁnding is another indication that theWM115-RAGE cells have
developed metastatic features and led us to investigate the level of the
tumor suppressor p53, which is expressed as wild type in WM115
cells [59]. We observed lower levels of p53 in the WM115-RAGE cells
than in control cells, in agreement with earlier studies that showed
that S100B down-regulates p53 inmelanoma cells [60–62]. Interesting-
ly, a recent study has shown that p53 deﬁciency in the A375Pmetastatic
melanoma cells resulted in increased migration and invasion of these
cells and is in line with our results [63].
Downstream RAGE signaling is complex and not yet fully under-
stood. Several intracellular proteins such as ERK1/2, Diaphanous-1
(Dia-1), TIRAP and MyD88, have been suggested to play the role of
adaptor proteins of RAGE [64–66]. While Dia-1 was shown to promote
cellular migration of C6 glioma through the activation of Rac-1 and
cdc42 [65], it is not known if this interaction is relevant in melanoma
cells. Sakagushi et al. recently described that they could not immuno-
precipitate Dia-1 from HEK-293 cells overexpressing RAGE [66]. To
test a possible effect of RAGE overexpression on Dia-1, we measured
Dia-1 protein levels in cell lysates of WM115-MOCK and WM115-
RAGE cells. Western blot analysis did not reveal differences in Dia-1
expression levels between the two cell lines (data not shown).
The activation of the Ras/BRAF/ERK signaling pathways is a central
mechanism leading to cell proliferation and survival and promoting
anchorage independent growth, migration and invasion [41,67–71]. In
melanoma, the Ras/RAF/ERK signaling pathway is constitutively activat-
ed in more than 60% of melanoma cells, includingWM115 andWM266
cells, due to gain of functionmutations in B-RAF (BRAFV600E) [72–74]. Our
analysis of signaling pathways thatweremodulated upon overexpression
of RAGE, showed a signiﬁcant decrease in the phosphorylated form of
ERK1/2. We propose that the decrease of ERK1/2 activity reﬂects the de-
crease in proliferation of WM115-RAGE cells. Interestingly, a decrease in
phosphorylated levels of ERK1/2 also correlated with a decrease in cellu-
lar proliferation in MC3T3-E1 osteoblast cells overexpressing RAGE [75].
In melanoma, cellular proliferation is also under the control of PI3K/
AKT [76,77]. In our experimental conditions, we could not detect chang-
es in activity of the AKT kinase, suggesting that the PI3K/AKT pathway is
not involved in the changes of proliferation ormigration observedwhen
RAGE is overexpressed. Since JNK has also been shown to be activated in
melanoma, at times through ERK signaling, we also determined the
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changes in the WM115-RAGE cells compared to the control cells [78].
These data suggest that RAGE overexpression modulates the ERK path-
ways without affecting the JNK and AKT pathways.
The observed increases in migration, invasion and anchorage
independent cellular proliferation of melanoma cells occurred in the
absence of exogenous ligand and correlated with the level of RAGE ex-
pression. Recent evidence strongly suggests that RAGE oligomerization
is required for activation of the receptor [79–86], and for example, it
has been shown that on the surface of HEK293 and HeLa cells, RAGE
exists as constitutive dimers [87,88] and that oligomerization of the
receptor could be further enhanced following stimulation with S100B
or AGEs [88]. We propose that when overexpressed in the melanoma
WM115 cells, RAGE spontaneously forms higher order oligomers
which are sufﬁcient to trigger RAGE signaling. In this case, RAGE oligo-
merization could thus result in ligand-independent RAGE activation.
This hypothesis is also supported by our observation that the anti-RAGE
antibodies, used in this study, were not able to suppress increases in cel-
lularmigrationwhereas treatment of the cells with RAGE targeting siRNA
did reduce cellularmigration. RAGE oligomerization is currently an active
area of research and several mechanisms of oligomerization-dependent
RAGE activation have been proposed: RAGE oligomerization could occur
either through the V domains [84], C1 domains [84,89] or the C2 domains
of the receptor [85,86] in a ligand dependent manner [85]. We propose
here that RAGE oligomerization could also be a means for RAGE to
generate intracellular signaling in the absence of interaction with its li-
gands. Although ligand-induced receptor oligomerization is a common
mechanism of signaling, as observedwith the epithelial growth factor re-
ceptor [90], several studies have also reported ligand-independent recep-
tor signaling caused by receptor oligomerization [91–93]. For example,
overexpression of CD30 was found to be sufﬁcient to mediate signaling
inHodgkin–Reed–Sternberg cells through oligomerization of the receptor
[92]. RAGE could therefore represent a new paradigm of receptor that ex-
hibits ligand-independent activation through receptor oligomerization.
Further studies would be necessary to elucidate the mechanisms of
RAGE oligomerization in the RAGE overexpressing melanoma cells.
In conclusion, our data support the hypothesis that RAGE up-
regulation in primary melanoma cells triggers a metastatic switch
with increasemigration and reduced proliferation.Our data also suggest
that RAGE overexpression can lead to ligand independent RAGE activa-
tion, possibly through oligomerization of the receptor. We will further
investigate the mechanisms of ligand independent RAGE activation in
model cells.
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